KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Amortization of Deferred Charges (2018 - 2020)

Historic Amortization of Deferred Charges for Castle Biosciences (CSTL) over the last 3 years, with Q4 2020 value amounting to $173000.0.

  • Castle Biosciences' Amortization of Deferred Charges fell 2606.84% to $173000.0 in Q4 2020 from the same period last year, while for Sep 2021 it was $173000.0, marking a year-over-year decrease of 8077.78%. This contributed to the annual value of $839000.0 for FY2020, which is 5641.56% down from last year.
  • As of Q4 2020, Castle Biosciences' Amortization of Deferred Charges stood at $173000.0, which was down 2606.84% from $214000.0 recorded in Q3 2020.
  • In the past 5 years, Castle Biosciences' Amortization of Deferred Charges registered a high of $916000.0 during Q2 2019, and its lowest value of $139273.0 during Q3 2018.
  • Over the past 3 years, Castle Biosciences' median Amortization of Deferred Charges value was $226000.0 (recorded in 2020), while the average stood at $304320.2.
  • Per our database at Business Quant, Castle Biosciences' Amortization of Deferred Charges surged by 21664.43% in 2019 and then plummeted by 7510.92% in 2020.
  • Castle Biosciences' Amortization of Deferred Charges (Quarter) stood at $139929.0 in 2018, then skyrocketed by 67.23% to $234000.0 in 2019, then fell by 26.07% to $173000.0 in 2020.
  • Its Amortization of Deferred Charges stands at $173000.0 for Q4 2020, versus $214000.0 for Q3 2020 and $228000.0 for Q2 2020.